Hemp Industry Statistics (2026): Market Size, Sales, Acreage, and the Ban

Total U.S. demand for hemp-derived cannabinoid products reached $28.4 billion, according to Whitney Economics' 2023 U.S. National Cannabinoid Report — a survey-based estimate built from more than 800 operators across 45 states, and the number the industry, Congress, and most news coverage cite. For scale, that made hemp-derived cannabinoids larger than the entire legal adult-use and medical marijuana market that year, and the same report put the industry's total economic impact at more than $79 billion. Whitney notes the figure is conservative, because it excludes demand flowing through gas stations, grocery stores, and convenience stores — precisely the channels where intoxicating hemp sold hardest.

The firm's 2026 update, published as the federal ban loomed, raised the stakes: Whitney Economics estimated the 2025 hemp product market at $37.5–50.9 billion in its conservative scenario and $47.3–64.1 billion in its higher scenario, with total economic impact of $91.5–153.9 billion. Those are wide ranges, and that's the honest way to present them — this is a market with no federal sales reporting, measured by survey and model rather than by receipts. The direction, though, is unambiguous: in the five states Whitney tracked closely (Florida, Texas, Illinois, North Carolina, Tennessee), retailer counts rose 36% and retail revenue 79% between 2023 and 2025. Whatever the true national number, the market that H.R. 5371 addresses grew fast right up until the law passed.

The part of the hemp market the November 2026 ban actually targets — intoxicating hemp-derived cannabinoids — has its own numbers, tracked most closely by cannabis analytics firm Brightfield Group. Brightfield put U.S. sales of delta-8 THC and other hemp-derived cannabinoids at $200.5 million in 2020 and roughly $2.8 billion in 2023 — a 1,283% increase in three years — with the market reaching about $3.5 billion in 2024 and projected (pre-ban) to hit $4.4 billion by 2029. Delta-8 THC alone generated about $1.2 billion in 2023, roughly 44% of the segment (Brightfield Group, 2023).

The fastest-growing corner was drinkable: hemp-derived THC beverages nearly quadrupled from $102 million in 2023 to $382 million in 2024, with Brightfield projecting $750 million by 2029 — a forecast made before the ban was law and now contingent on it. THC seltzers in liquor stores and grocery chains were the industry's mainstreaming story of 2024–2025, which is part of why the political reaction arrived when it did.

One reconciliation note, because sharp readers will spot it: Brightfield's segment figures ($2.8–3.5 billion) are much smaller than Whitney's whole-market figures ($28 billion and up). They measure different things — Brightfield tracks branded intoxicating-hemp product sales it can observe; Whitney models total demand across every hemp-derived cannabinoid product and channel, CBD included. Cite whichever matches your claim, and name the firm either way.

CBD — the non-intoxicating cannabinoid that built the first hemp boom — remains the fuzziest number in the industry, because analysts disagree on what counts. Statista's market outlook puts U.S. CBD product revenue at about $3.0 billion in 2025, while Precedence Research estimates the U.S. cannabidiol market at $7.68 billion for the same year. That spread isn't sloppiness so much as definition: oils-and-gummies-only versus every CBD-infused product in every channel. The defensible citation is the range, with both firms named.

What's not in dispute is adoption. 14% of American adults said they personally use CBD products in Gallup's 2019 survey — rising to 20% of adults under 30 — figures Gallup collected at the height of the first CBD wave and which remain the cleanest national adoption numbers available. On the regulatory side, the FDA has approved exactly one CBD-derived prescription drug (Epidiolex, for rare seizure disorders) and has repeatedly stated that CBD cannot lawfully be added to conventional foods or marketed as a dietary supplement (FDA, 2023 position) — a limbo that persisted right up to the 2025 rewrite of the hemp definition.

Now the farm numbers, which run on a completely different scale from the retail market. USDA's National Hemp Report valued 2025 U.S. hemp production at $739 million, up 64% from 2024 (USDA NASS, April 2026 release). Growers planted 49,267 acres in the open and harvested 43,707 (up 34% year over year). The engine is floral hemp — the flower grown for cannabinoid extraction — which produced 33.2 million pounds worth $574 million in 2025, nearly 90% of open-field value. Hemp grown under protection (greenhouses) added $93.3 million, up 225% in a single year.

The trend line tells the industry's whole boom-bust-boom story:

Read that top row carefully, because it's the most misquoted stat in hemp: 511,442 acres were licensed in 2019 at the peak of the CBD gold rush (Vote Hemp), but licensed is not planted — Vote Hemp itself estimated only about 230,000 acres actually went in the ground that year, and far less was successfully harvested. The CBD price collapse then wiped out most of that acreage; by the USDA's first National Hemp Report (2021 crop year), harvested acreage was down to 33,480. The 2024–2025 recovery is real but different in kind: grain production more than doubled in 2025 (7.26 million pounds, +112%), seed value nearly tripled (+193%), while fiber value actually fell 13% despite more acres (USDA, 2026) — and floral hemp for cannabinoids, the segment the federal ban hits hardest, drove most of the value growth. Which means the crop's best year since 2021 happened in the final season before the rules change.

The hemp-derived cannabinoid industry supported 328,000 American jobs paying $13 billion in wages in 2023, per Whitney Economics' U.S. National Cannabinoid Report — and the firm's 2026 update estimates 375,000–473,000 jobs in 2025. The same 2023 report calculated that states collected about $1.5 billion in sales tax from hemp products in 2022 — revenue that vanishes wherever the products do.

The best state-level snapshot is Texas, the industry's largest battleground market. Whitney Economics' March 2025 analysis for the Texas Hemp Business Council found the Texas hemp industry generating $5.5 billion in annual revenue ($4.3 billion of it retail), supporting 53,300 jobs and $2.1 billion in wages, with a total state economic impact of $10.3 billion across roughly 8,500 hemp-related businesses. One state, in other words, accounts for a meaningful slice of the national industry — and Texas hemp retail grew about 30% between 2023 and 2025 even while its legislature debated banning it.

Adoption data is thinner for hemp than for cannabis generally, but two well-sourced numbers anchor it. First, the Gallup figure above: 14% of U.S. adults reported using CBD products (Gallup, 2019), skewing young. Second — and more troubling — the teen data: 11.4% of U.S. 12th graders reported past-year use of delta-8 THC in 2023, according to a JAMA-published analysis of Monitoring the Future data by USC and University of Michigan researchers, supported by NIDA (2024). Among those teens, 35.4% had used delta-8 ten or more times in the year, and about 91% also used marijuana.

The geographic pattern in that study is the part regulators quote: teen delta-8 use ran higher in Southern and Midwestern states, in states without their own delta-8 rules, and in states without legal adult-use marijuana — the exact map of where intoxicating hemp filled the gap left by prohibition. Whatever your view of the 2026 ban, that finding is a large part of why Congress acted: an intoxicating product with no federal age gate had found its way to one in nine high-school seniors.

Long before Congress moved, the states were already redrawing the map. By late 2023, 17 states had banned delta-8 THC outright and another 7 had restricted it severely enough to keep ordinary products off open retail shelves, per CBD Oracle's state-by-state legal analysis — meaning nearly half the country had acted against the flagship intoxicating-hemp product while it remained federally legal. The mechanics varied: Colorado banned the isomerization process that converts CBD into delta-8; Idaho banned essentially anything containing any THC; California and Connecticut folded delta-8 into their licensed marijuana systems (CBD Oracle, 2023).

The count kept climbing through 2024 and 2025 as legislatures piled on age limits, testing rules, milligram caps, and outright bans — a moving target we won't pin to a single number without a single dated source. The stable, citable fact is the direction: state-level restriction of intoxicating hemp expanded every year from 2021 onward, and the federal ban arrived on top of — not instead of — that patchwork. For what it means where you live, our state-by-state guide tracks the layer underneath the federal rules.

The defining statistic of the industry's next chapter is a date and a milligram figure. H.R. 5371 — the continuing appropriations package signed November 12, 2025 — rewrites the federal definition of hemp effective November 12, 2026 (Congress.gov, 2025). Three provisions do the work, as law-firm analyses (Perkins Coie, 2025) lay out: the 2018 Farm Bill's delta-9-only test becomes a total THC standard (THCa counts, which ends THCa flower); synthesized and converted cannabinoids — delta-8, HHC, and kin — are written out of the hemp definition entirely; and finished consumer products are capped at roughly 0.4 milligrams of total THC per container. A single ordinary hemp gummy carries 5–10 mg, so the cap isn't a trim — as written, it removes the intoxicating-hemp shelf.

How much of the market does that eliminate? The U.S. Hemp Roundtable — the industry's main trade group — estimates the new definition excludes about 95% of hemp cannabinoid products, threatening a $28.4 billion industry, more than 300,000 jobs, and roughly $1.5 billion in state tax revenue (U.S. Hemp Roundtable, 2025; the underlying market figures are Whitney's). Those are advocacy numbers from the losing side of the vote, so weight them accordingly — but note they're built on the same Whitney Economics baseline everyone else cites, and no analyst disputes that the 0.4 mg cap covers the overwhelming majority of products now sold.

Two data points frame what happens next. First, substitution: Whitney Economics' 2026 analysis found that in states that banned hemp products, marijuana sales did not increase — consumers went online or across state lines instead, a relief valve a federal ban doesn't offer. Second, the timeline is still politically live: delay and rewrite efforts continued through 2026, so treat every figure in this section as "as the law stands now." The full consumer playbook — what dies, what survives, what to do — is in our November 2026 ban guide.

Three habits keep hemp statistics honest. First, never mix the crop and the market. "The hemp industry is worth $739 million" and "the hemp industry is worth $28 billion" are both real numbers — one is USDA farm-gate production value, the other is Whitney's retail-demand estimate — and swapping them is the most common error in hemp coverage. Second, name the firm and the year, because these are modeled figures that get revised: "$28.4 billion (Whitney Economics, 2023)" is bulletproof; "the multibillion-dollar hemp industry" is mush. Third, date everything relative to November 12, 2026 — every market statistic on this page describes an industry whose legal foundation changes on that date, so a 2025 sales figure quoted without that context will mislead by omission within the year.

If a number here looks stale, that's the design — we date precisely so you can tell, and we update this page as the USDA, the analysts, and Congress move. This is general information, not legal or financial advice, and state rules layer on top of everything federal described here.